Clinical trials · California
Cancer clinical trials in California
We’re tracking 1,311 recruiting cancer studies with a site in California — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT06828185Recruiting
Comparing two surgery methods for testicular cancer
This trial compares two ways of doing surgery (radical orchiectomy) for testicular cancer. One method is the standard approach and the other spares a layer of muscle tissue. The study looks at patient experiences and recovery.
Loma Linda, CaliforniaAges 18 years+ - NCT06336928Recruiting
Blood test validation for breast cancer diagnosis
This study is testing a new blood test (liquid biopsy) to see if it can accurately detect breast cancer or track remission. If you are a woman getting a mammogram, have an abnormal finding, were recently diagnosed, or are in remission after treatment, you may be able to join and help validate this test.
Newport Beach, CaliforniaAges 18 years+ - NCT06337942Recruiting
Bladder or kidney-bladder transplant from a deceased donor
This trial offers a first-in-human transplant of a bladder or a kidney combined with a bladder from a deceased donor. It is for people with severe bladder problems or bladder cancer who already need a new bladder or are on immune-suppressing medicines for a prior organ transplant.
Los Angeles, CaliforniaAges 18–70 - NCT06353386RecruitingPhase 1/Phase 2
Opevesostat combinations for advanced prostate cancer
This study tests a new drug called opevesostat, alone or combined with other treatments, for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It aims to see if it can help control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06353997RecruitingPhase 2
New immunotherapy combination before surgery for triple-negative breast cancer
This trial tests a new combination of two immunotherapy drugs (INBRX-106 and pembrolizumab) given before surgery for people with early-stage triple-negative breast cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Los Angeles, CaliforniaAges 18 years+ - NCT06376565Recruiting
Improving colonoscopy follow-up for high-risk polyps
This study aims to understand why some people return for a follow-up colonoscopy after having high-risk colon polyps and to find ways to improve the process. It involves interviews and testing new approaches to ensure patients get the right follow-up care.
Los Angeles, CaliforniaAges 21 years+ - NCT06384222RecruitingPhase 2
MRI scan to monitor response to abiraterone before prostate surgery
This trial tests whether a special MRI scan can show how well the drug abiraterone works against high-risk prostate cancer before surgery. If you have high-risk prostate cancer that hasn't spread, you might be able to take abiraterone for a few months and then have a prostatectomy, with the MRI helping your doctor see the drug's effect.
San Francisco, CaliforniaAges 18 years+ - NCT06389123RecruitingPhase 1
Targeted imaging and therapy for metastatic cancers
This trial tests a new imaging scan and a targeted radiation treatment for certain cancers that have spread. First, a special PET scan finds tumors that light up; then, if eligible, you may receive a treatment that targets those same tumors.
Sacramento, CaliforniaAges 18 years+ - NCT06408220Recruiting
Stomach cancer risk check for minority groups
This study checks if you are at high risk for stomach cancer. You will give blood samples and have a stomach exam (endoscopy) to look for early signs.
Duarte, CaliforniaAges 40–80 - NCT06413680RecruitingPhase 1/Phase 2
Study of REGN10597 with or without cemiplimab for advanced solid tumors
This study tests a new drug called REGN10597, either alone or with cemiplimab, for people with advanced solid tumors (like melanoma or kidney cancer) that have not responded to standard treatments. The goal is to see if the combination can shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT06417190RecruitingPhase 2
Bladder preservation trial for muscle-invasive bladder cancer with variant histology
This trial tests a bladder-sparing approach for people with muscle-invasive bladder cancer that has a variant histology type. The goal is to avoid removing the bladder by using a combination of treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT06418204Recruiting
Cannabis use study for cancer patients in community clinics
This study looks at the benefits and risks of using cannabis or cannabinoids for cancer patients. It aims to help understand how these products affect symptoms and quality of life during chemotherapy or immunotherapy.
Fresno, CaliforniaAges 18 years+ - NCT06432985Recruiting
Smoking Cessation Program for Veterans with Cancer
This study tests a video-based program to help Veterans who smoke and are being treated for cancer or lung cancer screening to quit. If you're a VA patient in San Francisco and currently smoke, you may be able to join.
San Francisco, CaliforniaAges 18 years+ - NCT06448754RecruitingPhase 2
Volrustomig for first-line advanced lung cancer
This trial tests a new drug called volrustomig, which helps your immune system fight cancer, as a first treatment for advanced non-small cell lung cancer. It's for people whose tumors do not have certain gene changes (like EGFR) that have other targeted treatments available.
Los Angeles, CaliforniaAges 18–130 - NCT06462365RecruitingPhase 1
Preventing GvHD after stem cell transplant for blood cancers
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
Duarte, CaliforniaAges 18 years+ - NCT06476808RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests an investigational drug (BMS-986463) in people with advanced solid tumors. It aims to find a safe dose and see if it helps shrink or control the cancer. You must be well enough to do daily activities and have a tumor that can be biopsied before treatment starts.
Los Angeles, CaliforniaAges 18 years+ - NCT05482893RecruitingPhase 1/Phase 2
Spevatamig for advanced stomach, pancreas, or bile duct cancer
This trial tests a new drug called Spevatamig (PT886), alone or with different chemotherapy and/or immunotherapy combinations, for people with certain advanced stomach, pancreatic, or bile duct cancers. The goal is to see if it shrinks tumors and is safe.
Duarte, CaliforniaAges 18 years+ - NCT03603223RecruitingPhase 2
Pembrolizumab for abnormal mouth patches that may become cancer
This Phase 2 trial studies pembrolizumab (an immune medicine) for leukoplakia and related abnormal mouth patches with moderate/severe pre-cancer changes. It aims to see whether the treatment can shrink or control the lesions when surgery or radiation isn’t an option.
La Jolla, CaliforniaAges 18 years+ - NCT06989437RecruitingPhase 2/Phase 3
Study of Ponsegromab for Pancreatic Cancer with Weight Loss
This study tests an experimental drug called ponsegromab for people with advanced pancreatic cancer who experience severe weight loss and fatigue. It aims to see if the drug can help improve weight and energy levels while you continue standard chemotherapy.
Encinitas, CaliforniaAges 18 years+ - NCT06525220RecruitingPhase 3
New drug combo vs. standard for head and neck cancer
This trial tests a new combination of two immunotherapy drugs (petosemtamab plus pembrolizumab) compared to pembrolizumab alone for people with head and neck cancer that has spread or come back and cannot be cured locally. It may be an option if your cancer has a certain protein (PD-L1) and you haven't had prior cancer treatment for this stage.
Palo Alto, CaliforniaAges 18 years+ - NCT06542835Recruiting
Telehealth support for colorectal cancer screening
This study tests whether telehealth support can help people get recommended colorectal cancer screening. It may be a good fit if you haven't been screened recently and are willing to use your phone for health guidance.
Los Angeles, CaliforniaAges 45–64 - NCT06553872RecruitingPhase 2
Pirtobrutinib and CAR T-cell therapy for mantle cell lymphoma
This trial tests if adding the targeted therapy pirtobrutinib before CAR T-cell treatment (Tecartus) works better for mantle cell lymphoma that has come back or not responded to other treatments. It aims to improve outcomes for patients who are eligible for CAR T-cell therapy.
Stanford, CaliforniaAges 18 years+ - NCT06561685RecruitingPhase 1
Study of LY4050784 for Advanced Solid Tumors with SMARCA4 Changes
This trial tests a new drug, LY4050784, for people with advanced solid tumors that have a specific change in a gene called SMARCA4 (BRG1). The study aims to see if the drug is safe and effective. It may be an option for those who have tried other treatments or have no standard options left.
Santa Monica, CaliforniaAges 18 years+ - NCT06567743RecruitingPhase 2
Study of a new virus therapy for high-risk bladder cancer
This trial tests a new virus-based medicine, cretostimogene grenadenorepvec, given directly into the bladder for people with high-risk non-muscle-invasive bladder cancer. It may help prevent the cancer from coming back, especially for those who have not had BCG treatment or whose cancer did not respond to BCG.
Orange, CaliforniaAges 18 years+
Cancer trials by city in California
Where these studies are running in California
Institutions with a site for the recruiting cancer studies listed above.
- USC / Norris Comprehensive Cancer Center · 5 studies
- City of Hope Comprehensive Cancer Center · 3 studies
- UC San Diego Moores Cancer Center · 3 studies
- University of California, Los Angeles (UCLA) · 3 studies
- Cedars-Sinai Medical Center · 2 studies
- Providence Medical Foundation · 2 studies
- UCLA / Jonsson Comprehensive Cancer Center · 2 studies
- University of California, Irvine Medical Center / UC Irvine Health · 2 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in California?
- Yes. We're currently tracking 1,311 recruiting cancer studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.